Circulating CD14^high CD16^low intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progression.

ABSTRACT:

Background

Besides the interest of an early detection of ovarian cancer, there is an urgent need for new predictive and prognostic biomarkers of tumor development and cancer treatment. In healthy patients, circulating blood monocytes are typically subdivided into classical (85%), intermediate (5%) and non-classical (10%) populations. Although these circulating monocyte subsets have been suggested as biomarkers in several diseases, few studies have investigate their potential as a predictive signature for tumor immune status,tumor growth and treatment adaptation.

Methods

In this study, we used a homogeneous cohort of 28 chemotherapy-naïve patients with ovarian cancer to evaluate monocyte subsets as biomarkers of the ascites immunological status. We evaluated the correlations

SUBMITTER: Prat M 

PROVIDER: S-EPMC7279676 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature